The Pharmacy Times® Prostate Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that occurs in the prostate.
July 2nd 2024
FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC).
Cancer Diagnoses Significantly Decreased in First Few Months of COVID-19 Pandemic
September 14th 2023Investigators found an approximately 23% decrease in overall cancer incidence in April 2020, specifically for breast, colon, rectal, head and neck cancers, as well as melanoma and endocrine cancer diagnoses.
Read More
Merck Discontinues Trials of Pembrolizumab in Prostate Cancer, Non–Small Cell Lung Cancer
March 13th 2023The KEYNOTE-641 and -789 trials did not demonstrate improvements or meet the primary endpoints in metastatic castration-resistant prostate cancer and metastatic nonsquamous non–small cell lung cancer.
Read More
Olaparib Combination Shows Increased Median Overall Survival in Fatal Metastatic Prostate Cancer
February 21st 2023Olaparib with abiraterone increased survival in patients with metastatic prostate cancer compared to the current standard of care, according to a session at the ASCO Genitourinary Cancers Symposium.
Read More